Description

Immunoglobulin (Ig) therapies are among the oldest therapeutic moieties employed in a broad range of pathological conditions. Immunoglobulin G (IgG) holds the highest share (44%) in the global blood plasma market, with a revenue of $9.24 billion. Currently, the global Ig market is dominated by three major companies, holding about 85% of the total market share. The growing incidence of epidemic outbreaks caused by pathogens has positioned Ig therapy as a primary area of focus in meeting future healthcare demands. With an ever increasing demand for Ig products, companies are looking for novel advances in drug delivery technologies and manufacturing processes to survive and succeed in this competitive landscape.